Atul Dandekar
CIK: 0002050167
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Maze Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (39 total)
- Oct 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct6.6K shares at avg. $10.42$69K - Oct 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct857 shares at avg. $10.42$9K - Oct 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct7.5K shares at avg. $32.07$241K - Sep 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct7.5K shares at avg. $10.42$78K - Sep 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct7.5K shares at avg. $27.06$203K - Sep 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct36 shares at avg. $25.81$929.16 - Sep 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct3.2K shares at avg. $26.01$83K - Sep 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct2.8K shares at avg. $26.38$74K - Sep 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct391 shares at avg. $27.12$11K - Sep 1, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct12.5K shares- - Jul 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct7.1K shares at avg. $27.31$194K - Jul 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct400 shares at avg. $27.89$11K - Jul 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct7.5K shares at avg. $10.42$78K - Jun 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct7.5K shares at avg. $10.42$78K - Jun 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct7.5K shares at avg. $28.02$210K - May 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct7.5K shares at avg. $10.42$78K - May 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct7.5K shares at avg. $26.34$198K - May 4, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct6K shares at avg. $10.42$62K - May 4, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct8.3K shares at avg. $10.42$87K - Apr 29, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct7.5K shares at avg. $25.37$190K - Apr 29, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct7.5K shares at avg. $10.42$78K - Mar 30, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct7.5K shares at avg. $10.42$78K - Mar 30, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct790 shares at avg. $30.02$24K - Mar 30, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct6.7K shares at avg. $29.26$196K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
19K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 6,643 | $10.42 | $69,220 | Direct |
| Oct 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 857 | $10.42 | $8,930 | Direct |
| Oct 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 7,500 | $32.07 | $240,532 | Direct |
| Sep 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 7,500 | $10.42 | $78,150 | Direct |
| Sep 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 7,500 | $27.06 | $202,921 | Direct |
| Sep 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 36 | $25.81 | $929 | Direct |
| Sep 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 3,207 | $26.01 | $83,425 | Direct |
| Sep 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,800 | $26.38 | $73,853 | Direct |
| Sep 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 391 | $27.12 | $10,604 | Direct |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 12,500 | - | $0 | Direct |
| Jul 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 7,100 | $27.31 | $193,875 | Direct |
| Jul 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 400 | $27.89 | $11,156 | Direct |
| Jul 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 7,500 | $10.42 | $78,150 | Direct |
| Jun 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 7,500 | $10.42 | $78,150 | Direct |
| Jun 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 7,500 | $28.02 | $210,150 | Direct |
| May 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 7,500 | $10.42 | $78,150 | Direct |
| May 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 7,500 | $26.34 | $197,554 | Direct |
| May 4, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 5,985 | $10.42 | $62,364 | Direct |
| May 4, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 8,320 | $10.42 | $86,694 | Direct |
| Apr 29, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 7,500 | $25.37 | $190,299 | Direct |
| Apr 29, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 7,500 | $10.42 | $78,150 | Direct |
| Mar 30, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 7,500 | $10.42 | $78,150 | Direct |
| Mar 30, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 790 | $30.02 | $23,714 | Direct |
| Mar 30, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 6,710 | $29.26 | $196,305 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Award(A) Restricted Stock Units | 19,000 | - | - | Direct |
1-25 of 39 transactions
About Dandekar Atul
Dandekar Atul (SEC CIK 0002050167) files insider reports with the SEC as CSBO of Maze Therapeutics, Inc. (MAZE).
Signal8 holds 15 ownership filings by Dandekar Atul (1 Form 3, 14 Form 4), filed between Jan 30, 2025 and Oct 30, 2026. Those filings report 39 transactions, from Sep 22, 2025 to Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Dandekar Atul's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Dandekar Atul
- Oct 29, 2026: Option exercises of MAZE shares (2 lines, Form 4, code M).
- Oct 29, 2026: Open-market sale of MAZE shares (Form 4, code S).
- Sep 29, 2026: Option exercise of MAZE shares (Form 4, code M).
- Sep 29, 2026: Open-market sale of MAZE shares (Form 4, code S).
- Sep 3, 2026: Open-market sales of MAZE shares (2 lines, Form 4, code S).
Other insiders filing for Maze Therapeutics, Inc. (MAZE)
- Coloma Jason V, Chief Executive Officer
- Bernstein Harold, President, R&D & CMO
- Courtney Phillips, GC and Corp. Secretary
- Kornowski Sophie, Director
- Johnson Paula A, Director
- SPIEGELMAN DANIEL K, Director